'This field is in its infancy': Amgen noncommittal on oral obesity med until phase 1 data arrive

Amgen is, for now, staying the course with its two-pronged obesity development plan as the marketplace for arguably the most hyped class of drugs in decades continues to form. But executives were noncommittal about future development of an oral option, saying the plan will be based on the quality of a phase 1 readout in 2024.